Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 2.44
CYNO's Cash to Debt is ranked higher than
60% of the 319 Companies
in the Global Medical Devices industry.

( Industry Median: 2.42 vs. CYNO: 2.44 )
Ranked among companies with meaningful Cash to Debt only.
CYNO' s Cash to Debt Range Over the Past 10 Years
Min: 2.24  Med: 79.15 Max: N/A
Current: 2.44
Equity to Asset 0.78
CYNO's Equity to Asset is ranked higher than
76% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. CYNO: 0.78 )
Ranked among companies with meaningful Equity to Asset only.
CYNO' s Equity to Asset Range Over the Past 10 Years
Min: 0.48  Med: 0.80 Max: 0.87
Current: 0.78
0.48
0.87
Interest Coverage 19.08
CYNO's Interest Coverage is ranked lower than
62% of the 195 Companies
in the Global Medical Devices industry.

( Industry Median: 38.74 vs. CYNO: 19.08 )
Ranked among companies with meaningful Interest Coverage only.
CYNO' s Interest Coverage Range Over the Past 10 Years
Min: 14.7  Med: 9999.00 Max: N/A
Current: 19.08
F-Score: 6
Z-Score: 7.91
M-Score: -2.82
WACC vs ROIC
13.83%
6.69%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 8.18
CYNO's Operating margin (%) is ranked higher than
65% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 2.65 vs. CYNO: 8.18 )
Ranked among companies with meaningful Operating margin (%) only.
CYNO' s Operating margin (%) Range Over the Past 10 Years
Min: -27.9  Med: 2.72 Max: 15.75
Current: 8.18
-27.9
15.75
Net-margin (%) 5.09
CYNO's Net-margin (%) is ranked higher than
61% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 1.06 vs. CYNO: 5.09 )
Ranked among companies with meaningful Net-margin (%) only.
CYNO' s Net-margin (%) Range Over the Past 10 Years
Min: -31.25  Med: 1.97 Max: 11.67
Current: 5.09
-31.25
11.67
ROE (%) 4.84
CYNO's ROE (%) is ranked higher than
57% of the 297 Companies
in the Global Medical Devices industry.

( Industry Median: 1.21 vs. CYNO: 4.84 )
Ranked among companies with meaningful ROE (%) only.
CYNO' s ROE (%) Range Over the Past 10 Years
Min: -17.23  Med: 1.76 Max: 14.04
Current: 4.84
-17.23
14.04
ROA (%) 3.75
CYNO's ROA (%) is ranked higher than
64% of the 319 Companies
in the Global Medical Devices industry.

( Industry Median: -0.01 vs. CYNO: 3.75 )
Ranked among companies with meaningful ROA (%) only.
CYNO' s ROA (%) Range Over the Past 10 Years
Min: -14.3  Med: 1.34 Max: 11.19
Current: 3.75
-14.3
11.19
ROC (Joel Greenblatt) (%) 25.85
CYNO's ROC (Joel Greenblatt) (%) is ranked higher than
79% of the 314 Companies
in the Global Medical Devices industry.

( Industry Median: 4.86 vs. CYNO: 25.85 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CYNO' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -54.37  Med: 10.74 Max: 60.47
Current: 25.85
-54.37
60.47
Revenue Growth (3Y)(%) 10.40
CYNO's Revenue Growth (3Y)(%) is ranked higher than
74% of the 232 Companies
in the Global Medical Devices industry.

( Industry Median: 3.90 vs. CYNO: 10.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
CYNO' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -13.1  Med: 13.70 Max: 24.8
Current: 10.4
-13.1
24.8
EBITDA Growth (3Y)(%) 13.50
CYNO's EBITDA Growth (3Y)(%) is ranked higher than
66% of the 194 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. CYNO: 13.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CYNO' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -74  Med: 16.10 Max: 87.3
Current: 13.5
-74
87.3
EPS Growth (3Y)(%) -4.00
CYNO's EPS Growth (3Y)(%) is ranked lower than
56% of the 195 Companies
in the Global Medical Devices industry.

( Industry Median: 3.20 vs. CYNO: -4.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CYNO' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -41.1  Med: 1.85 Max: 210.1
Current: -4
-41.1
210.1
» CYNO's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-10-27)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

CYNO Guru Trades in Q2 2015

Robert Olstein 101,000 sh (New)
Jim Simons Sold Out
Paul Tudor Jones Sold Out
Mario Gabelli 10,844 sh (-4.93%)
Chuck Royce 105,000 sh (-55.83%)
» More
Q3 2015

CYNO Guru Trades in Q3 2015

Ken Fisher 94,601 sh (New)
Paul Tudor Jones 6,800 sh (New)
Chuck Royce 105,000 sh (unchged)
Mario Gabelli 10,844 sh (unchged)
Robert Olstein 101,000 sh (unchged)
» More
Q4 2015

CYNO Guru Trades in Q4 2015

Ken Fisher 114,213 sh (+20.73%)
Mario Gabelli 10,844 sh (unchged)
Paul Tudor Jones Sold Out
Robert Olstein 56,000 sh (-44.55%)
Chuck Royce 1,500 sh (-98.57%)
» More
Q1 2016

CYNO Guru Trades in Q1 2016

Steven Cohen 535,400 sh (New)
Joel Greenblatt 58,566 sh (New)
Paul Tudor Jones 5,052 sh (New)
Ken Fisher 114,213 sh (unchged)
Chuck Royce Sold Out
Mario Gabelli 10,581 sh (-2.43%)
Robert Olstein 49,600 sh (-11.43%)
» More
» Details

Insider Trades

Latest Guru Trades with CYNO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices
Compare:NAS:BABY, NAS:ZLTQ, OTCPK:IOBCF, NAS:CNMD, NAS:LDRH, NAS:INGN, NAS:HTWR, NAS:SPNC, NAS:OFIX, NAS:MDXG, NAS:VASC, OTCPK:MCRPF, NAS:KTWO, NYSE:ITGR, NAS:CSII, NYSE:CRY, NYSE:PEN, OTCPK:MZRTF, NAS:GNMK, NAS:XENT » details
Traded in other countries:C9S.Germany,
Cynosure Inc develops & markets aesthetic treatment systems that enable plastic surgeons, dermatologists & other medical practitioners to perform non-invasive & minimally invasive procedures to remove hair, treat vascular & benign pigmented lesion, etc.

Cynosure Inc was incorporated in July 1991. The Company develops and markets aesthetic treatment systems that enable plastic surgeons, dermatologists and other medical practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, liquefy and remove unwanted fat through laser lipolysis, reduce cellulite, clear nails infected by toe fungus and ablate sweat glands. It has also developed an aesthetic treatment product for the home use market. The Company sells its products through a direct sales force in North America, France, Spain, the United Kingdom, Germany, Australia, Korea, China, Japan and Mexico and through international distributors in approximately 120 other countries. Its product portfolio is composed of various energy sources including Alexandrite, diode, Nd:YAG, picosecond, pulse dye, and Q-switched lasers and intense pulsed light. It offers single energy source systems as well as workstations that incorporate two or more different types of lasers or pulsed light technologies. It offers multiple technologies and system alternatives at various price points depending mainly on the number and type of energy sources included in the system. Its products are designed to be easily upgradeable to add additional energy sources and handpieces, which provide its customers with technological flexibility as it expand their practices. The Company's latest innovations are SmartLipo system and PicoSure system. The Company's flagship products include Elite, Affirm/SmartSkin, Cynergy, Accolade. The Company sells its aesthetic treatment systems to the traditional physician customer base of dermatologists and plastic surgeons as well as to non-traditional physician customers who are providing aesthetic services using laser and light-based technology. Non-traditional physician customers can include primary care physicians, obstetricians and gynecologists. As of December 31, 2013, the Company owns over 60 United States patents, as well as many United States pending applications and foreign patents and pending applications. It is also joint owners with El.En. of certain patents and pending applications. The Company competes with Cutera, Solta Medical, Syneron Medical, ZELTIQ Aesthetics, Alma Lasers among others. Its products are medical devices subject to extensive and rigorous regulation by the U.S. Food and Drug Administration, or FDA, as well as other regulatory bodies.

Top Ranked Articles about Cynosure Inc

Steven Cohen Invests in Cynosure Purchase makes him company's leading guru shareholder
Steven Cohen (Trades, Portfolio) of Point72 Asset Management invested in a 731,500-share stake in Cynosure Inc. (NASDAQ:CYNO), a Westford, Massachusetts-based company that manufactures aesthetic medical devices, for a price of $46.27 per share on April 25. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 64.65
CYNO's P/E(ttm) is ranked lower than
83% of the 172 Companies
in the Global Medical Devices industry.

( Industry Median: 28.34 vs. CYNO: 64.65 )
Ranked among companies with meaningful P/E(ttm) only.
CYNO' s P/E(ttm) Range Over the Past 10 Years
Min: 5.38  Med: 34.96 Max: 630.2
Current: 64.65
5.38
630.2
Forward P/E 39.37
CYNO's Forward P/E is ranked lower than
85% of the 55 Companies
in the Global Medical Devices industry.

( Industry Median: 24.63 vs. CYNO: 39.37 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 64.65
CYNO's PE(NRI) is ranked lower than
82% of the 171 Companies
in the Global Medical Devices industry.

( Industry Median: 28.88 vs. CYNO: 64.65 )
Ranked among companies with meaningful PE(NRI) only.
CYNO' s PE(NRI) Range Over the Past 10 Years
Min: 5.38  Med: 34.96 Max: 630.2
Current: 64.65
5.38
630.2
Price/Owner Earnings (ttm) 45.85
CYNO's Price/Owner Earnings (ttm) is ranked lower than
63% of the 107 Companies
in the Global Medical Devices industry.

( Industry Median: 32.52 vs. CYNO: 45.85 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
CYNO' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 16.47  Med: 40.48 Max: 195.05
Current: 45.85
16.47
195.05
P/B 2.94
CYNO's P/B is ranked higher than
51% of the 327 Companies
in the Global Medical Devices industry.

( Industry Median: 2.95 vs. CYNO: 2.94 )
Ranked among companies with meaningful P/B only.
CYNO' s P/B Range Over the Past 10 Years
Min: 0.46  Med: 1.84 Max: 4.96
Current: 2.94
0.46
4.96
P/S 3.50
CYNO's P/S is ranked higher than
51% of the 320 Companies
in the Global Medical Devices industry.

( Industry Median: 3.51 vs. CYNO: 3.50 )
Ranked among companies with meaningful P/S only.
CYNO' s P/S Range Over the Past 10 Years
Min: 0.5  Med: 2.12 Max: 5.45
Current: 3.5
0.5
5.45
PFCF 41.70
CYNO's PFCF is ranked lower than
69% of the 96 Companies
in the Global Medical Devices industry.

( Industry Median: 31.08 vs. CYNO: 41.70 )
Ranked among companies with meaningful PFCF only.
CYNO' s PFCF Range Over the Past 10 Years
Min: 8.58  Med: 28.93 Max: 164.2
Current: 41.7
8.58
164.2
POCF 29.60
CYNO's POCF is ranked lower than
69% of the 134 Companies
in the Global Medical Devices industry.

( Industry Median: 20.58 vs. CYNO: 29.60 )
Ranked among companies with meaningful POCF only.
CYNO' s POCF Range Over the Past 10 Years
Min: 5.75  Med: 23.07 Max: 1420
Current: 29.6
5.75
1420
EV-to-EBIT 40.78
CYNO's EV-to-EBIT is ranked lower than
69% of the 172 Companies
in the Global Medical Devices industry.

( Industry Median: 22.17 vs. CYNO: 40.78 )
Ranked among companies with meaningful EV-to-EBIT only.
CYNO' s EV-to-EBIT Range Over the Past 10 Years
Min: -183  Med: 8.70 Max: 311.7
Current: 40.78
-183
311.7
EV-to-EBITDA 24.23
CYNO's EV-to-EBITDA is ranked lower than
63% of the 181 Companies
in the Global Medical Devices industry.

( Industry Median: 18.09 vs. CYNO: 24.23 )
Ranked among companies with meaningful EV-to-EBITDA only.
CYNO' s EV-to-EBITDA Range Over the Past 10 Years
Min: -305.5  Med: 15.30 Max: 441.3
Current: 24.23
-305.5
441.3
PEG 0.69
CYNO's PEG is ranked higher than
88% of the 74 Companies
in the Global Medical Devices industry.

( Industry Median: 3.18 vs. CYNO: 0.69 )
Ranked among companies with meaningful PEG only.
CYNO' s PEG Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 0
Current: 0.69
Shiller P/E 236.72
CYNO's Shiller P/E is ranked lower than
98% of the 45 Companies
in the Global Medical Devices industry.

( Industry Median: 41.87 vs. CYNO: 236.72 )
Ranked among companies with meaningful Shiller P/E only.
CYNO' s Shiller P/E Range Over the Past 10 Years
Min: 92  Med: 165.70 Max: 236.72
Current: 236.72
92
236.72
Current Ratio 3.03
CYNO's Current Ratio is ranked higher than
55% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 2.83 vs. CYNO: 3.03 )
Ranked among companies with meaningful Current Ratio only.
CYNO' s Current Ratio Range Over the Past 10 Years
Min: 1.67  Med: 4.07 Max: 7.09
Current: 3.03
1.67
7.09
Quick Ratio 2.10
CYNO's Quick Ratio is ranked higher than
51% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 2.05 vs. CYNO: 2.10 )
Ranked among companies with meaningful Quick Ratio only.
CYNO' s Quick Ratio Range Over the Past 10 Years
Min: 0.87  Med: 3.36 Max: 5.83
Current: 2.1
0.87
5.83
Days Inventory 178.76
CYNO's Days Inventory is ranked lower than
68% of the 279 Companies
in the Global Medical Devices industry.

( Industry Median: 134.88 vs. CYNO: 178.76 )
Ranked among companies with meaningful Days Inventory only.
CYNO' s Days Inventory Range Over the Past 10 Years
Min: 157.29  Med: 176.34 Max: 289.61
Current: 178.76
157.29
289.61
Days Sales Outstanding 38.40
CYNO's Days Sales Outstanding is ranked higher than
89% of the 270 Companies
in the Global Medical Devices industry.

( Industry Median: 68.74 vs. CYNO: 38.40 )
Ranked among companies with meaningful Days Sales Outstanding only.
CYNO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 42.42  Med: 55.97 Max: 92.51
Current: 38.4
42.42
92.51
Days Payable 58.43
CYNO's Days Payable is ranked higher than
50% of the 262 Companies
in the Global Medical Devices industry.

( Industry Median: 62.25 vs. CYNO: 58.43 )
Ranked among companies with meaningful Days Payable only.
CYNO' s Days Payable Range Over the Past 10 Years
Min: 23.04  Med: 53.49 Max: 84.75
Current: 58.43
23.04
84.75

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 6.72
CYNO's Price/Net Current Asset Value is ranked lower than
51% of the 249 Companies
in the Global Medical Devices industry.

( Industry Median: 7.14 vs. CYNO: 6.72 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CYNO' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.73  Med: 2.67 Max: 6.46
Current: 6.72
0.73
6.46
Price/Tangible Book 4.39
CYNO's Price/Tangible Book is ranked lower than
51% of the 302 Companies
in the Global Medical Devices industry.

( Industry Median: 4.19 vs. CYNO: 4.39 )
Ranked among companies with meaningful Price/Tangible Book only.
CYNO' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.56  Med: 2.25 Max: 4.59
Current: 4.39
0.56
4.59
Price/Projected FCF 2.55
CYNO's Price/Projected FCF is ranked lower than
54% of the 129 Companies
in the Global Medical Devices industry.

( Industry Median: 2.23 vs. CYNO: 2.55 )
Ranked among companies with meaningful Price/Projected FCF only.
CYNO' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.98  Med: 1.54 Max: 2.09
Current: 2.55
0.98
2.09
Price/Median PS Value 1.65
CYNO's Price/Median PS Value is ranked lower than
77% of the 302 Companies
in the Global Medical Devices industry.

( Industry Median: 1.05 vs. CYNO: 1.65 )
Ranked among companies with meaningful Price/Median PS Value only.
CYNO' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.31  Med: 0.98 Max: 2.41
Current: 1.65
0.31
2.41
Price/Graham Number 3.55
CYNO's Price/Graham Number is ranked lower than
69% of the 147 Companies
in the Global Medical Devices industry.

( Industry Median: 2.28 vs. CYNO: 3.55 )
Ranked among companies with meaningful Price/Graham Number only.
CYNO' s Price/Graham Number Range Over the Past 10 Years
Min: 0.65  Med: 1.79 Max: 9.62
Current: 3.55
0.65
9.62
Earnings Yield (Greenblatt) (%) 2.44
CYNO's Earnings Yield (Greenblatt) (%) is ranked higher than
66% of the 341 Companies
in the Global Medical Devices industry.

( Industry Median: -0.40 vs. CYNO: 2.44 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CYNO' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.3  Med: 3.80 Max: 3389.1
Current: 2.44
0.3
3389.1

More Statistics

Revenue (TTM) (Mil) $385.9
EPS (TTM) $ 0.85
Beta1.66
Short Percentage of Float7.03%
52-Week Range $29.00 - 55.94
Shares Outstanding (Mil)23.52

Analyst Estimate


Warning: Invalid argument supplied for foreach() in /home/gurufocu/public_html/modules/stock/estimate.php on line 163
Dec16 Dec17
Revenue (Mil $) 432 457
EPS ($) 1.40 1.93
EPS w/o NRI ($) 1.40 1.93
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for CYNO

Headlines

Articles On GuruFocus.com
Steven Cohen Invests in Cynosure Apr 26 2016 
Robert Olstein's Olstein Strategic Opportunities Fund Q4 Commentary Mar 11 2016 
Cynosure Inc. (CYNO) CFO Timothy W Baker buys 2,500 Shares Feb 27 2009 
Cynosure Inc. (CYNO) CEO Michael R Davin buys 2,500 Shares Feb 27 2009 
Cynosure: A Value Play on Vanity Jan 18 2009 

More From Other Websites
Edited Transcript of CYNO earnings conference call or presentation 26-Jul-16 1:00pm GMT Jul 26 2016
Cynosure, Inc. (Nasdaq: CYNO) to Ring The Nasdaq Stock Market Closing Bell Jul 26 2016
Cynosure, Inc. (Nasdaq: CYNO) to Ring The Nasdaq Stock Market Closing Bell Jul 26 2016
Cynosure Reports Net Income of $6.3 Million on Record Sales of $110.3 Million for the Second Quarter... Jul 26 2016
Cynosure beats Street 2Q forecasts Jul 26 2016
Cynosure beats Street 2Q forecasts Jul 26 2016
CYNOSURE INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Jul 26 2016
Cynosure Receives Approval to Market SculpSure® in South Korea Jul 26 2016
Cynosure Reports Net Income of $6.3 Million on Record Sales of $110.3 Million for the Second Quarter... Jul 26 2016
Cynosure Receives Approval to Market SculpSure® in South Korea Jul 26 2016
Q2 2016 Cynosure Inc Earnings Release - Before Market Open Jul 26 2016
Cynosure To Host Second-Quarter 2016 Financial Results Conference Call On July 26 Jul 23 2016
CYNOSURE INC Files SEC form 8-K, Change in Directors or Principal Officers Jul 22 2016
ETF’s with exposure to Cynosure, Inc. : July 21, 2016 Jul 21 2016
Cynosure To Host Second-Quarter 2016 Financial Results Conference Call On July 26 Jul 14 2016
Cynosure Receives Health Canada Authorization to Market SculpSure® Jul 13 2016
Cynosure Receives Health Canada Authorization to Market SculpSure® Jul 13 2016
New Trial Agreement with Cynosure Private Equity - 11 July 2016 Jul 10 2016
Cynosure, Inc. breached its 50 day moving average in a Bullish Manner : CYNO-US : July 1, 2016 Jul 01 2016
ETF’s with exposure to Cynosure, Inc. : June 30, 2016 Jun 30 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)